Novo Nordisk A/S (NYSE:NVO) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Novo Nordisk A/S (NYSE:NVO) have been assigned a consensus recommendation of “Hold” from the twenty-seven ratings firms that are covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $102.85.

Several research firms have recently issued reports on NVO. The Goldman Sachs Group reissued a “neutral” rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Thursday, June 4th. Jefferies Financial Group reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Cfra cut Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price objective on the stock. in a research note on Tuesday, September 22nd. Finally, Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy showed significant liver-health benefits. In a STEP UP trial analysis presented at EASD, 88.5% of adults with obesity and elevated liver fat reached normal levels after 72 weeks of injectable Wegovy, while liver fat declined by nearly two-thirds. The findings could expand Wegovy’s clinical value beyond weight loss. Wegovy liver-fat study
• Positive Sentiment: The Wegovy pill produced additional weight loss for patients switching from injections. Real-world data showed adults switching from Wegovy or Eli Lilly’s Zepbound injections lost roughly 4.1% of their body weight over three months, supporting Novo’s effort to compete in the growing oral obesity-drug market. Wegovy pill switching study
• Positive Sentiment: CagriSema data reinforced Novo’s next-generation obesity pipeline. The combination treatment reportedly delivered 22.4% weight loss and reduced “food noise,” while also showing potential organ and bone-health benefits. CagriSema data
• Positive Sentiment: Additional pipeline and cardiovascular evidence may support the franchise. A real-world analysis indicated lower observed major cardiovascular-event risk for patients increasing Ozempic to 2 mg versus switching to Mounjaro, while a new Hengrui licensing agreement adds an oral GLP-1/GIP candidate.
• Neutral Sentiment: EASD highlighted both opportunity and competition. New data from Novo and Eli Lilly could expand the GLP-1 market, but investors are closely comparing the companies’ products and pipelines. Novo is also reportedly open to acquisitions, though no specific transaction has been announced.
• Negative Sentiment: Analyst caution and competitive risks continue to weigh on NVO. Deutsche Bank reaffirmed its “sell” rating, and commentary has criticized Novo’s outlook as uninspiring. Roche and Eli Lilly are emerging as increasingly formidable competitors in obesity treatments, limiting enthusiasm for the positive trial data.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $37.39 on Friday. The company has a 50-day simple moving average of $44.86 and a 200 day simple moving average of $43.86. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.66 and a current ratio of 0.87. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16. The company has a market capitalization of $166.95 billion, a PE ratio of 9.14, a price-to-earnings-growth ratio of 1.24 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The company had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. On average, research analysts predict that Novo Nordisk A/S will post 3.54 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were issued a $0.5786 dividend. This represents a yield of 258.0%. This is a decrease from Novo Nordisk A/S’s previous dividend of $1.2751. The ex-dividend date was Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 20.05%.

Institutional Trading of Novo Nordisk A/S

Large investors have recently bought and sold shares of the company. Godfrey Financial Associates Inc. purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $25,000. Scarborough Advisors LLC bought a new stake in Novo Nordisk A/S during the first quarter worth about $26,000. Continuum Advisory LLC purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth approximately $38,000. Markowski Investments purchased a new stake in shares of Novo Nordisk A/S in the second quarter worth $43,000. Finally, Cassaday & Co Wealth Management LLC bought a new stake in Novo Nordisk A/S during the 1st quarter valued at about $45,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.